CASI Pharmaceuticals Inc.

1.79-0.0200-1.10%Vol 920.92K1Y Perf 5.52%
Apr 16th, 2021 16:00 DELAYED
BID1.79 ASK1.80
Open1.82 Previous Close1.81
Pre-Market- After-Market1.82
 - -  0.03 1.68%
Target Price
4.00 
Analyst Rating
Strong Buy 1.00
Potential %
123.46 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/100/100 
Value Ranking
★★★+     54.94
Insiders Value % 3/6/12 mo.
-/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/100/100 
Income Ranking
 —    -
Market Cap250.24M 
Earnings Rating
Neutral
Price Range Ratio 52W %
13.52 
Earnings Date
10th May 2021

Today's Price Range

1.721.85

52W Range

1.463.90

5 Year PE Ratio Range

-15.20-6.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-11.82%
1 Month
-25.42%
3 Months
-47.20%
6 Months
8.48%
1 Year
5.52%
3 Years
-74.17%
5 Years
49.17%
10 Years
-62.71%

TickerPriceChg.Chg.%
CASI1.79-0.0200-1.10
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
8.90
9.30
0.01
0.02
165.00
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
36.60
-350.10
-331.90
-
-
RevenueValueIndustryS&P 500US Markets
11.74M
0.08
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.07-0.12-71.43
Q03 2020-0.06-0.14-133.33
Q02 2020-0.08-0.0712.50
Q01 2020-0.11-0.0918.18
Q04 2019-0.11-0.13-18.18
Q03 2019-0.11-0.109.09
Q02 2019-0.09-0.10-11.11
Q01 2019-0.09-0.090.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.0614.29Positive
6/2021 QR-0.0712.50Positive
12/2021 FY-0.240.00-
12/2022 FY-0.2822.22Positive
Next Report Date10th May 2021
Estimated EPS Next Report-0.06
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume920.92K
Shares Outstanding139.80M
Trades Count4.24K
Dollar Volume999.04K
Avg. Volume1.16M
Avg. Weekly Volume927.80K
Avg. Monthly Volume3.03M
Avg. Quarterly Volume1.27M

CASI Pharmaceuticals Inc. (NASDAQ: CASI) stock closed at 1.79 per share at the end of the most recent trading day (a -1.1% change compared to the prior day closing price) with a volume of 923.52K shares and market capitalization of 250.24M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 125 people. CASI Pharmaceuticals Inc. CEO is Wei-Wu He.

The one-year performance of CASI Pharmaceuticals Inc. stock is 5.52%, while year-to-date (YTD) performance is -39.32%. CASI stock has a five-year performance of 49.17%. Its 52-week range is between 1.46 and 3.9, which gives CASI stock a 52-week price range ratio of 13.52%

CASI Pharmaceuticals Inc. currently has a PE ratio of -4.70, a price-to-book (PB) ratio of 3.51, a price-to-sale (PS) ratio of 22.40, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.33%, a ROC of -54.20% and a ROE of -59.98%. The company’s profit margin is -%, its EBITDA margin is -331.90%, and its revenue ttm is $11.74 Million , which makes it $0.08 revenue per share.

Of the last four earnings reports from CASI Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.06 for the next earnings report. CASI Pharmaceuticals Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for CASI Pharmaceuticals Inc. is Strong Buy (1), with a target price of $4, which is +123.46% compared to the current price. The earnings rating for CASI Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CASI Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CASI Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.54, ATR14 : 0.20, CCI20 : -122.98, Chaikin Money Flow : 0.18, MACD : -0.31, Money Flow Index : 48.19, ROC : -10.05, RSI : 33.31, STOCH (14,3) : 10.00, STOCH RSI : 0.38, UO : 44.43, Williams %R : -90.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CASI Pharmaceuticals Inc. in the last 12-months were: Larry Zhang (Buy at a value of $38 291), Wei-Wu He (Buy at a value of $18 877 612), Weihao Xu (Buy at a value of $15 417)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

CEO: Wei-Wu He

Telephone: +1 240 864-2600

Address: 9620 Medical Center Drive, Rockville 20850, MD, US

Number of employees: 125

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

58%42%

Bearish Bullish

50%50%

News

Stocktwits